NCT00444873View on ClinicalTrials.gov

Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly

PHASE3CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Acromegaly
Interventions
DRUG

lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval

Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.

Trial Locations (1)

80336

Klinikum Innenstadt, Munich

Sponsors

Lead Sponsor

Ipsen
All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT00444873 - Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly | Biotech Hunter | Biotech Hunter